Royalty Pharma 10-Q 7 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 01, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'RPRX	'
Entity Common Stock, Shares Outstanding	'	23,009,882
Entity Registrant Name	'REPROS THERAPEUTICS INC.	'
Entity Central Index Key	'0000897075	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current Assets	'	'
Cash and cash equivalents	$81,828	$24,212
Prepaid expenses and other current assets	193	406
Total current assets	82,021	24,618
Fixed assets, net	87	53
Other assets, net	2,734	2,161
Total assets	84,842	26,832
Current Liabilities	'	'
Accounts payable	2,829	3,240
Accrued expenses	382	558
Total current liabilities	3,211	3,798
Commitments and contingencies (note 5)	'	'
Stockholders' Equity	'	'
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding	0	0
Common Stock, $.001 par value, 75,000,000 shares authorized, 23,121,959and 17,272,505 shares issued, respectively and 23,009,609 and 17,160,155 shares outstanding, respectively	23	17
Additional paid-in capital	313,469	234,299
Cost of treasury stock, 112,350 shares	-1,380	-1,380
Deficit accumulated during the development stage	-230,481	-209,902
Total stockholders' equity	81,631	23,034
Total liabilities and stockholders' equity	$84,842	$26,832

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, issued	0	0
Preferred Stock, outstanding	0	0
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	23,121,959	17,272,505
Common Stock, shares outstanding	23,009,609	17,160,155
Treasury stock, shares	112,350	112,350

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		313 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenues	'	'	'	'	'
Licensing fees	$0	$0	$0	$0	$28,755
Product royalties	0	0	0	0	627
Research and development grants	0	0	0	0	1,219
Interest income	3	1	6	1	16,308
Gain on disposal of fixed assets	0	0	0	0	102
Other Income	0	0	0	0	1,003
Total revenues and other income	3	1	6	1	48,014
Expenses	'	'	'	'	'
Research and development	4,786	3,131	17,132	6,776	212,391
General and administrative	1,215	1,453	3,453	3,348	56,373
Other Expense	0	0	0	0	388
Total expenses	6,001	4,584	20,585	10,124	269,152
Loss from continuing operations	-5,998	-4,583	-20,579	-10,123	-221,138
Loss from discontinued operations	0	0	0	0	-1,828
Gain on disposal of discontinued operation	0	0	0	0	939
Net loss before cumulative effect of change in accounting principle	-5,998	-4,583	-20,579	-10,123	-222,027
Cumulative effect of change in accounting principle	0	0	0	0	-8,454
Net loss	($5,998)	($4,583)	($20,579)	($10,123)	($230,481)
Loss per share - basic and diluted:	($0.26)	($0.30)	($1.03)	($0.69)	'
Weighted average shares used in loss per share calculation:	'	'	'	'	'
Basic	23,006	15,422	20,066	14,746	'
Diluted	23,006	15,422	20,066	14,746	'

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Deficit Accumulated During the Development Stage
In Thousands, except Share data
Beginning Balance at Dec. 31, 2011	$4,666	$12	$197,769	($1,380)	($191,735)
Beginning Balance (in shares) at Dec. 31, 2011	'	12,470,694	'	112,350	'
Stock based option compensation	1,902	0	1,902	0	0
Issuance of 100 shares of common stock at a share price of $5.07 (in shares)	'	100	'	0	'
Issuance of shares of common stock, net of offering costs (in shares)	'	2,463,537	'	0	'
Exercise of stock options to purchase common stock for cash	121	0	121	0	0
Exercise of stock options to purchase common stock for cash (in shares)	'	16,488	'	0	'
Issuance of shares of common stock for the cashless exercise of stock options (in shares)	'	11,173	'	0	'
Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share	301	0	301	0	0
Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares)	'	121,079	'	0	'
Issuance of shares of common stock, net of offering costs 1	23,018	2	23,016	0	0
Issuance of shares of common stock, net of offering costs 1 (in shares)	'	2,145,636	'	0	'
Issuance of shares of common stock, net of offering costs	10,310	3	10,307	0	0
Net loss	-10,123	0	0	0	-10,123
Ending Balance at Sep. 30, 2012	30,195	17	233,416	-1,380	-201,858
Ending Balance (in shares) at Sep. 30, 2012	'	17,228,707	'	112,350	'
Beginning Balance at Dec. 31, 2012	23,034	17	234,299	-1,380	-209,902
Beginning Balance (in shares) at Dec. 31, 2012	'	17,272,505	'	112,350	'
Stock based option compensation	2,258	0	2,258	0	0
Issuance of shares of common stock, net of offering costs (in shares)	'	4,312,500	'	0	'
Issuance of 871,634 shares of common stock for the cashless exercise of 872,133 Series A Warrants	0	1	-1	0	0
Issuance of 871,634 shares of common stock for the cashless exercise of 872,133 Series A Warrants (in shares)	'	871,634	'	0	'
Issuance of 614,564 shares of common stock for the cashless exercise of 716,463 Series B Warrants	0	1	-1	0	0
Issuance of 614,564 shares of common stock for the cashless exercise of 716,463 Series B Warrants (in shares)	'	614,564	'	0	'
Exercise of stock options to purchase common stock for cash	47	0	47	0	0
Exercise of stock options to purchase common stock for cash (in shares)	'	2,500	'	0	'
Issuance of shares of common stock for the cashless exercise of stock options (in shares)	'	5,407	'	0	'
Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share	107	0	107	0	0
Exercise of Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares)	'	42,849	'	0	'
Issuance of shares of common stock, net of offering costs	76,764	4	76,760	0	0
Net loss	-20,579	0	0	0	-20,579
Ending Balance at Sep. 30, 2013	$81,631	$23	$313,469	($1,380)	($230,481)
Ending Balance (in shares) at Sep. 30, 2013	'	23,121,959	'	112,350	'

CONSOLIDATED_STATEMENTS_OF_STO1

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Issuance of 871,634 shares of common stock for the cashless exercise of Series A Warrants	872,133	'
Issuance of shares of common stock for the cashless exercise of Series B Warrants stock options	716,463	'
Exercise of Series B Warrants to purchase common stock for cash, share price	$2.49	$2.49
Issuance of shares of common stock for the cashless exercise of stock options	8,332	27,915
Issuance of shares of common stock, offering costs	$5,200,000	$777
Issuance of 100 shares of common stock at a share price	'	$5.07
Exercise of stock option to purchase common stock for cash, share price	$18.74	'
Sale Of Stock Price Per Shares	'	$4.50
Sale Of Stock Price Per Shares 1	'	$11
Issuance of shares of common stock, offering costs 1	'	$586
Maximum [Member]	'	'
Exercise of stock option to purchase common stock for cash, share price	'	$10.88
Minimum [Member]	'	'
Exercise of stock option to purchase common stock for cash, share price	'	$1.33

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		313 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash Flows from Operating Activities	'	'	'
Net loss	($20,579)	($10,123)	($230,481)
Gain on disposal of discontinued operations	0	0	-939
Gain on disposal of fixed assets	0	0	-102
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Noncash financing costs	0	0	316
Noncash inventory impairment	0	0	4,417
Noncash patent impairment	0	0	2,614
Noncash other income	0	0	-709
Noncash decrease in accounts payable	0	0	-1,308
Depreciation and amortization	177	106	4,478
Noncash stock-based compensation	2,258	1,902	14,576
Common stock issued for agreement not to compete	0	0	200
Series B Preferred Stock issued for consulting services	0	0	18
Changes in operating assets and liabilities (net effects of purchase of businesses in 1988 and 1994):	'	'	'
Increase in receivables	0	0	-199
Increase in inventory	0	0	-4,447
(Increase) decrease in prepaid expenses and other current assets	213	-352	110
Increase (decrease) in accounts payable and accrued expenses	-532	367	11,087
Net cash used in operating activities	-18,463	-8,100	-200,369
Cash Flows from Investing Activities	'	'	'
Change in trading marketable securities	0	0	-191
Capital expenditures	-63	-54	-2,486
Purchase of other assets	-776	-578	-6,310
Proceeds from sale of PP&E	0	0	225
Cash acquired in purchase of FTI	0	0	3
Proceeds from sale of subsidiary, less $12,345 for operating losses during 1990 phase-out period	0	0	138
Proceeds from sale of the assets of FTI	0	0	2,250
Increase in net assets held for disposal	0	0	-213
Net cash used in investing activities	-839	-632	-6,584
Cash Flows from Financing Activities	'	'	'
Proceeds from issuance of common stock, net of offering costs	76,764	33,328	284,195
Exercise of stock options & warrants	154	422	951
Proceeds from a shareholder transaction	0	0	327
Proceeds from issuance of preferred stock	0	0	23,688
Purchase of treasury stock	0	0	-21,487
Proceeds from issuance of notes payable	0	0	2,839
Principal payments on notes payable	0	0	-1,732
Net cash provided by financing activities	76,918	33,750	288,781
Net increase in cash and cash equivalents	57,616	25,018	81,828
Cash and cash equivalents at beginning of period	24,212	4,565	0
Cash and cash equivalents at end of period	$81,828	$29,583	$81,828

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	313 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Proceeds from sale of subsidiary, operating losses during 1990 phase-out period	$12,345

Organization_Operations_and_Li

Organization, Operations and Liquidity	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Operations and Liquidity	'
	NOTE 1  —  Organization, Operations and Liquidity
	Repros Therapeutics Inc. (the “Company”, “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.
	Our primary product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound.  We are developing Androxal® for men of reproductive age with low testosterone levels.  Androxal® treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function.  We have completed two pivotal efficacy Phase 3 studies for Androxal® conducted under a Special Protocol Assessment (“SPA”).
	Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis.  We completed a low dose study in late 2011 to demonstrate both safety and signals of efficacy in low oral doses of Proellex® and in November 2012 we initiated a Phase 2 study in the treatment of endometriosis.  Additionally, we have completed a Phase 1/2 vaginal administration study for uterine fibroids in the first quarter of 2013.
	Our product development pipeline is summarized in the table below:
	Product Candidate (Indication)	Status	Next Expected Milestone(s)
	Androxal®
	Secondary Hypogonadism	Phase 3	Complete DEXA study (Q4 2014) pending FDA guidance
	Proellex®
	Uterine Fibroids	Phase 2B (vaginal)	Initiate a Phase 2B study (vaginal delivery) (Q1 2014)
		Phase 2 (oral)	Lift full clinical hold and initiate efficacy study (low dose oral) (Q1 2014)
	Endometriosis	Phase 2	Complete Phase 2 study (oral delivery) (Q3 2014)
	We also continue to maintain our patent portfolio of our phentolamine-based products for the treatment of sexual dysfunction.
	On June 25, 2013, we completed a public offering of 4,312,500 shares of our common stock at a price per share of $19.00.  Net proceeds to us, after deducting underwriter’s fees and offering expenses, were approximately $76.8 million.
	As of September 30, 2013, we had accumulated losses of $230.5 million, approximately $81.8 million in cash and cash equivalents, and our accounts payable and accrued expenses were approximately $3.2 million. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates through the NDA filing of both products.  We continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.

Patents_and_Patent_Application

Patents and Patent Applications	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Patents and Patent Applications	'
	NOTE  2  —  Patents and Patent Applications
	As of September 30, 2013, we had approximately $2,734,000 in capitalized patent and patent application costs reflected on its balance sheet.  Of this amount, $1,726,000 relates to patent and patent application costs for Androxal® and $1,008,000 relates to patent and patent application costs for Proellex®.
	Should we not continue development of either drug candidate or should we not continue as a going concern, the remaining capitalized patent and patent application costs may not be recoverable, which would result in charges to operating results in future periods.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2013
Accrued Expenses [Abstract]	'
Accrued Expenses	'
	NOTE  3  —  Accrued Expenses
	Accrued expenses consist of the following (in thousands):
		September 30, 2013		December 31, 2012
	Patent costs	$	152	$	245
	Research and development costs		87		192
	Personnel related costs		42		30
	Other		101		91
	Total	$	382	$	558

Loss_Per_Share

Loss Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Loss Per Share	'
	NOTE 4  —  Loss Per Share
	Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.  Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options.  In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.
	The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2013 and 2012 (in thousands, except per share amounts):
		Three Months Ended Sept. 30,				Nine Months Ended Sept. 30,
		2013		2012		2013		2012
	Net Loss	$	-5,998	$	-4,583	$	-20,579	$	-10,123
	Average common shares outstanding		23,006		15,422		20,066		14,746
	Basic and diluted loss per share	$	-0.26	$	-0.3	$	-1.03	$	-0.69
	Potential common stock of 3,975,430 and 5,264,207 common shares underlying stock options and warrants for the periods ended September 30, 2013 and 2012, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive.  Other potential common stock at September 30, 2013 includes Series A Warrants to purchase 877,137 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 810,109 shares of our common stock at an exercise price of $2.49 issued in February 2011.  Other potential common stock at September 30, 2012 includes Series A Warrants to purchase 1,749,270 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 1,569,421 shares of our common stock at an exercise price of $2.49 issued in February, 2011.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	NOTE 5  —   Commitments and Contingencies
	Therapeutic uses of our Androxal product candidate are covered in the United States by eight issued U.S. patents and four pending patent applications. Foreign coverage of therapeutic uses of our Androxal product candidate includes 61 issued foreign patents and 52 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Androxal (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of an anti-estrogen such as clomiphene citrate and others for use in the treatment of androgen deficiency and disorders related thereto. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. The PTO issued an Ex Parte Reexamination Certificate on April 29, 2013, cancelling the rejected claims and confirming patentability of the remaining claims. Nevertheless, we believe that our development of Androxal does not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims against the holder of such patents in a court of competent jurisdiction in order to develop Androxal further. Adverse determinations in litigation proceedings could require us to seek licenses from patent holders which may not be available on commercially reasonable terms, or at all, or may subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license Androxal until such patents expire or are otherwise no longer in force.
	On July 19, 2013, we received a letter from Dr. Harry Fisch threatening to file a lawsuit against us and two of our executive officers (Joseph S. Podolski, President and Chief Executive Officer and Ron Wiehle, Executive Vice President), seeking addition of Dr. Harry Fisch as an inventor on three of our patents, U.S. Patent Nos. 7,173,064, 7,737,185 and 7,759,360, covering therapeutic uses of Androxal®.  We believe that these allegations are without merit and on August 2, 2013, we commenced a lawsuit against Dr. Fisch in the U.S. District Court for the Southern District of Texas seeking a declaratory judgment that he should not be added as inventor to any of these patents.  On October 2, 2013, Dr. Fisch filed his answer and counterclaims to our complaint.  Dr. Fisch asserted counterclaims seeking correction of inventorship of the three patents at issue to name Dr. Fisch as a co-inventor of the applications leading these patents.  Dr. Fisch also seeks reasonable attorney’s fees.  Due to the preliminary status of the lawsuit and uncertainties related to litigation, we are unable to evaluate the likelihood of either a favorable or unfavorable outcome.

Organization_Operations_and_Li1

Organization, Operations and Liquidity (Tables)	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Product Development Pipeline	'
	Our product development pipeline is summarized in the table below:
	Product Candidate (Indication)	Status	Next Expected Milestone(s)
	Androxal®
	Secondary Hypogonadism	Phase 3	Complete DEXA study (Q4 2014) pending FDA guidance
	Proellex®
	Uterine Fibroids	Phase 2B (vaginal)	Initiate a Phase 2B study (vaginal delivery) (Q1 2014)
		Phase 2 (oral)	Lift full clinical hold and initiate efficacy study (low dose oral) (Q1 2014)
	Endometriosis	Phase 2	Complete Phase 2 study (oral delivery) (Q3 2014)

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Expenses [Abstract]	'
Accrued Expenses	'
	Accrued expenses consist of the following (in thousands):
		September 30, 2013		December 31, 2012
	Patent costs	$	152	$	245
	Research and development costs		87		192
	Personnel related costs		42		30
	Other		101		91
	Total	$	382	$	558

Loss_Per_Share_Tables

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Calculation of Loss Per Share	'
	The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2013 and 2012 (in thousands, except per share amounts):
		Three Months Ended Sept. 30,				Nine Months Ended Sept. 30,
		2013		2012		2013		2012
	Net Loss	$	-5,998	$	-4,583	$	-20,579	$	-10,123
	Average common shares outstanding		23,006		15,422		20,066		14,746
	Basic and diluted loss per share	$	-0.26	$	-0.3	$	-1.03	$	-0.69

Organization_Operations_and_Li2

Organization, Operations and Liquidity (Product Development Pipeline) (Details)	9 Months Ended
	Sep. 30, 2013
Androxal [Member] | Secondary Hypogonadism [Member]	'
Product Information [Line Items]	'
Status	'Phase 3
Next Expected Milestone(s)	'Complete DEXA study (Q4 2014) pending FDA guidance
Proellex [Member] | Uterine Fibroids 1 [Member]	'
Product Information [Line Items]	'
Status	'Phase 2B (vaginal)
Next Expected Milestone(s)	'Initiate a Phase 2B study (vaginal delivery) (Q1 2014)
Proellex [Member] | Uterine Fibroids 2 [Member]	'
Product Information [Line Items]	'
Status	'Phase 2 (oral)
Next Expected Milestone(s)	'Lift full clinical hold and initiate efficacy study (low dose oral) (Q1 2014)
Proellex [Member] | Endometriosis [Member]	'
Product Information [Line Items]	'
Status	'Phase 2
Next Expected Milestone(s)	'Complete Phase 2 study (oral delivery) (Q3 2014)

Organization_Operations_and_Li3

Organization, Operations and Liquidity (Additional Information) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011	Aug. 19, 1987	Jun. 25, 2013
						IPO [Member]
Product Information [Line Items]	'	'	'	'	'	'
Deficit accumulated during the development stage	($230,481,000)	($209,902,000)	'	'	'	'
Cash and cash equivalents	81,828,000	24,212,000	29,583,000	4,565,000	0	'
Accounts payable and accrued expenses	3,200,000	'	'	'	'	'
Common stock issued during the period	'	'	'	'	'	4,312,500
Price per share	'	'	$5.07	'	'	$19
Public Offering Net Proceeds	'	'	'	'	'	$76,800,000

Patents_and_Patent_Application1

Patents and Patent Applications (Additional Information) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Capitalized patent and patent application costs	$2,734,000	$2,161,000
Androxal [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Capitalized patent and patent application costs	1,726,000	'
Proellex [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Capitalized patent and patent application costs	$1,008,000	'

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule Of Accrued Liabilities [Line Items]	'	'
Patent costs	$152	$245
Research and development costs	87	192
Personnel related costs	42	30
Other	101	91
Total	$382	$558

Loss_Per_Share_Calculation_of_

Loss Per Share (Calculation of Loss Per Share) (Details) (USD $)	3 Months Ended		9 Months Ended		313 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Net loss	($5,998)	($4,583)	($20,579)	($10,123)	($230,481)
Average common shares outstanding	23,006	15,422	20,066	14,746	'
Basic and diluted loss per share	($0.26)	($0.30)	($1.03)	($0.69)	'

Loss_Per_Share_Additional_Info

Loss Per Share (Additional Information) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share Disclosure [Line Items]	'	'
Anti-dilutive shares of common stock excluded from computation of earning per share	3,975,430	5,264,207
Series A Warrants [Member]	'	'
Earnings Per Share Disclosure [Line Items]	'	'
Anti-dilutive shares of common stock excluded from computation of earning per share	877,137	1,749,270
Warrants, exercise price per share	0.01	0.01
Series B Warrants [Member]	'	'
Earnings Per Share Disclosure [Line Items]	'	'
Anti-dilutive shares of common stock excluded from computation of earning per share	810,109	1,569,421
Warrants, exercise price per share	2.49	2.49

Commitments_and_Contingencies_

Commitments and Contingencies (Additional Information) (Details)	Sep. 30, 2013
Domestic [Member]	'
Commitments and Contingencies [Line Items]	'
Number of patents	8
Number of pending patent applications	4
Foreign [Member]	'
Commitments and Contingencies [Line Items]	'
Number of patents	61
Number of pending patent applications	52
Third Party [Member]	'
Commitments and Contingencies [Line Items]	'
Number of patents	2